Download MendeleyStructure-guided development of selective caseinolytic protease P agonists as antistaphylococcal agents.
Zhang, T., Wang, P., Zhou, H., Wei, B., Zhao, Y., Li, J., Zhang, M., Wu, W., Lan, L., Gan, J., Yang, C.G.(2024) Cell Rep Med 5: 101837-101837
- PubMed: 39615486
- DOI: https://doi.org/10.1016/j.xcrm.2024.101837
- Primary Citation of Related Structures:
9IRM, 9IRP - PubMed Abstract:
Methicillin-resistant Staphylococcus aureus is a ubiquitous pathogen, posing a serious threat to human health worldwide. Thus, there is a high demand for antibiotics with distinct targets. Caseinolytic protease P (ClpP) is a promising target for combating staphylococcal infections; however, selectively activating S. aureus ClpP (SaClpP) rather than Homo sapiens ClpP (HsClpP) remains challenging. Herein, we rationally design and identify ZG297 by structure-based strategy. It binds and activates SaClpP instead of HsClpP. This is due to differentiated ligand binding attributed to crossed "tyrosine/histidine" amino acid pairs. ZG297 substantially inhibits the growth of a broad panel of S. aureus strains in vitro, outperforming the selective (R)-ZG197 agonist. ZG297 also functions as a potent antibiotic against multidrug-resistant S. aureus infections in Galleria mellonella larvae, zebrafish, murine skin, and thigh infection models. Collectively, we demonstrate that ZG297 is a safer and more potent antistaphylococcal agent than acyldepsipeptide 4 and (R)-ZG197.
Organizational Affiliation:
State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
